Breast Cancer Trial Results
Radiation Therapy Helps Prevent DCIS Recurrence After Breast-Conserving Surgery
(Posted: 03/10/2009) - The addition of radiation therapy to breast-conserving surgery halves the risk of a tumor recurrence compared with surgery alone in women with noninvasive breast tumors, according to a pooled analysis of trial results published January 21, 2009, by the Cochrane Reviews.
Removal of Ovaries and Fallopian Tubes Cuts Cancer Risk for BRCA1/2 Carriers
(Posted: 02/24/2009) - Surgery that removes the ovaries and fallopian tubes is one of the most effective ways to decrease a woman's risk of breast and gynecologic cancer if she carries a BRCA1 or BRCA2 gene mutation, according to the Jan. 21, 2009, Journal of the National Cancer Institute.
Zoledronic Acid Prevents Bone Loss During Estrogen-Suppression Treatment of Breast Cancer
(Posted: 01/09/2007, Updated: 09/16/2008) - Zoledronic acid can prevent treatment-induced bone loss in premenopausal women undergoing total estrogen suppression after surgery for hormone-responsive breast cancer, according to an article published online Jan. 3, 2007, in the Journal of Clinical Oncology.
Denosumab May Help Prevent Bone Loss Related to Use of Aromatase Inhibitors
(Posted: 09/11/2008) - Treatment with the experimental drug denosumab increased bone density in postmenopausal women taking aromatase inhibitors to prevent a recurrence of breast cancer, according to a report published online August 25, 2008, by the Journal of Clinical Oncology.
Taxane Combinations Marginally Better than Anthracyclines for Metastatic Breast Cancer
(Posted: 05/21/2008) - Combined data from eleven clinical trials showed that patients receiving taxanes for newly diagnosed metastatic breast cancer did marginally better than patients receiving anthracyclines, according to the April 20, 2008, Journal of Clinical Oncology.
(Posted: 03/10/2009) - The addition of radiation therapy to breast-conserving surgery halves the risk of a tumor recurrence compared with surgery alone in women with noninvasive breast tumors, according to a pooled analysis of trial results published January 21, 2009, by the Cochrane Reviews.
Removal of Ovaries and Fallopian Tubes Cuts Cancer Risk for BRCA1/2 Carriers
(Posted: 02/24/2009) - Surgery that removes the ovaries and fallopian tubes is one of the most effective ways to decrease a woman's risk of breast and gynecologic cancer if she carries a BRCA1 or BRCA2 gene mutation, according to the Jan. 21, 2009, Journal of the National Cancer Institute.
Zoledronic Acid Prevents Bone Loss During Estrogen-Suppression Treatment of Breast Cancer
(Posted: 01/09/2007, Updated: 09/16/2008) - Zoledronic acid can prevent treatment-induced bone loss in premenopausal women undergoing total estrogen suppression after surgery for hormone-responsive breast cancer, according to an article published online Jan. 3, 2007, in the Journal of Clinical Oncology.
Denosumab May Help Prevent Bone Loss Related to Use of Aromatase Inhibitors
(Posted: 09/11/2008) - Treatment with the experimental drug denosumab increased bone density in postmenopausal women taking aromatase inhibitors to prevent a recurrence of breast cancer, according to a report published online August 25, 2008, by the Journal of Clinical Oncology.
Taxane Combinations Marginally Better than Anthracyclines for Metastatic Breast Cancer
(Posted: 05/21/2008) - Combined data from eleven clinical trials showed that patients receiving taxanes for newly diagnosed metastatic breast cancer did marginally better than patients receiving anthracyclines, according to the April 20, 2008, Journal of Clinical Oncology.
